In the previous article, the editor has deeply interpreted Fosun Pharma’s recent big moves: holding hands with Intuitive Surgical, the originator of the world's surgical robots, with the purpose of "Made in China, joint research and development, and global sales". Overcome the worldwide problem of early diagnosis of lung cancer.

Please click the following link to review the full text of (Part 1):

Depth (Part 1): Guo Guangchang is holding hands with the originator of surgical robots in the world. Behind it is a big chess game that goes deep into the entire industry chain of AI, precision medicine, and health.

Fosun Dental's new digital product line

Chen Qiyu revealed Fosun Pharma’s layout ideas in an interview: “The Da Vinci Robotics business was cultivated by us over a period of 10 years. It can be said that the previous seven or eight years were the investment period. The Da Vinci product was brought to China. Through continuous education and training of excellent Chinese doctors, continuous dissemination in China, and establishment of the Da Vinci brand, it has today's preliminary situation. ”

This passage is a good interpretation of the long-term perspective of Fosun Pharma, aiming at the world’s top technologies, patience and perseverance in fine cultivation and operation, and finally ushering in the explosive growth of the layout. "In fact, we are very clear." strong>In the future, innovation is at the core of Fosun Pharma’s territory, that is, any new thing I make must be based on innovation, whether it is a robot or the laser medical equipment we are making now, it must be based on such a positioning Advancing. I feel that Fosun Pharma has not done enough in the field of medical devices in the past. Now we have taken corresponding measures to increase the research and development of innovative medical devices and global search goals. We are very concerned about two points in medical equipment: one is the marketing of advanced technology medical equipment and medical products in the Chinese market. We must grasp this, and use this end to understand the trends of the industry in real time; in addition, we must look for robots like this. After finding innovative products, we must resolutely seek cooperation. ”

At present, China's medical device field is in a period of rapid development. According to Chairman Zhao Zilin's introduction: “In recent years, the market size of medical equipment in my country has grown rapidly, reaching 480 billion yuan by 2015. It is expected that the market size will exceed 800 billion in 2020, and strive to become a powerful country in the development of medical equipment by 2025. The growth rate of our medical equipment is much higher than that of my country's GDP, with an annual growth rate of 15 to 20%. ”

Under such a general environment, the products that Fosun Pharma has cultivated and cultivated for a long time in the early stage are expected to usher in a harvest period.

The rapid growth of the medical device sector is expected, but from the perspective of Fosun Pharma as a whole, the core is pharmaceutical manufacturing and research and development. According to its 2016 semi-annual report, the pharmaceutical manufacturing and research and development sector accounted for nearly 70 % Of revenue accounted for. Fosun Pharma was founded in 1994 and has now developed into a comprehensive and leading healthcare industry group with business covering pharmaceutical manufacturing and R&D, medical services, medical diagnosis and medical devices, and pharmaceutical distribution and retail.

In the words of Chairman Chen Qiyu: “Fosun Pharmaceutical's business is very unique in all the medical and health industries in China, covering a wide range of strategic business links in the entire medical industry. Our pharmaceutical business is in a leading position in China's pharmaceutical industry, the medical device diagnosis industry is developing rapidly, and the medical service industry is also on a rapid development track. In addition, Sinopharm began to cooperate with China National Pharmaceutical Group to establish Sinopharm Holdings in 2003. Today, Sinopharm has become a listed company with more than RMB 200 billion in receivables. In the past ten years, we have continuously increased our investment in innovation and research and development. Innovation is not only the driving force of our business, but also the most important task of Fosun Pharma’s social responsibility. We publish a social responsibility report every year, and we always rank first in the social responsibility of China's pharmaceutical industry. As a leading medical and health company in China, we believe that the most important social responsibility is to innovate, to provide our Chinese patients and patients around the world with better medical solutions and more affordable medical solutions. In the past ten years, our investment in the pharmaceutical industry has continued to increase. Today, we are one of the companies with the largest R&D investment in China's pharmaceutical industry. In the next few years, we will continue to increase pharmaceutical R&D investment. ”

In fact, when I look closely at Fosun Pharma, I see that it has a very solid R&D foundation and industry-leading R&D investment. It is a company that has frequent highlights along the entire chain of the medical industry chain and penetrates into the industry.

Take a careful inventory. In the pharmaceutical manufacturing and R&D sector, Fosun Pharma has platforms such as Fuhong Henlius, Xingtai, Chongqing Medical Engineering Institute, and Fosun Pharma. Using global resources, Shanghai, Chongqing, Taipei, and San Francisco in the United States. The 24-hour joint research and development model focuses on the research and development of small molecule chemical innovative drugs, macromolecular biosimilar drugs, high-value generic drugs and specialty preparations.

Among them, Henlius is the leading monoclonal antibody platform in China. Just recently, in the field of biosimilar drugs, its self-developed injection-use recombinant anti-HER2 humanized monoclonal antibody breast cancer new drug has completed Phase I Clinical research, and officially launched Phase III clinical trials; in the field of innovative monoclonal antibodies, its first innovative bio-modified monoclonal antibody HLX07 was approved for clinical trials for colorectal cancer and other solid cancer indications. So far, The new drug has been clinically approved in China, Taiwan and the United States, and has achieved the international development strategy of research and development products through the three registration applications. In addition, Henlius has also added two innovative monoclonal antibodies through authorized cooperation with internationally renowned biomedical companies to further enhance its competitiveness in the anti-tumor field. This innovation team led by outstanding scientists has become a jewel in the field of Fosun Pharma's biopharmaceutical innovation.